She said early trials had shown retatrutide could achieve a higher percentage weight loss than the available GLP-1s such as Ozempic and Mounjaro, with results mimicking bariatric surgery weight loss
These advances have renewed interest in small-molecule oral GLP-1RAs
On arrival, the vial should be stored sealed at minus 20 degrees Celsius
The most commonly reported adverse effects in the Phase 2 trial included: Nausea the most prevalent side effect, particularly during dose escalation Vomiting Diarrhoea Constipation Decreased appetite (which, whilst contributing to weight loss, can be uncomfortable) Eructation (belching) Injection-site reactions (such as redness, bruising, or discomfort at the injection site) These effects are typically mild to moderate in severity and tend to be most pronounced during the first few weeks of treatment or following each dose increase
Modified from Mller et al.29 The GLP-1 receptor (rGLP-1) belongs to the B family of G protein-coupled receptors and is expressed in the pancreas, gastrointestinal tract, central nervous system (CNS), kidneys, lungs and heart